Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.18
0.2910.03%
Last update: Jun 8, 9:29 AM
Tvardi Therapeutics Inc Analyst Ratings
TVRDNASDAQ
Tvardi Therapeutics Analyst Ratings and Price Targets | NASDAQ:TVRD | Benzinga
Tvardi Therapeutics Inc has a consensus price target of $26.57 based on the ratings of 8 analysts. The high is $65 issued by Oppenheimer on May 21, 2025. The low is $3 issued by Barclays on April 20, 2026. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Barclays, and BTIG on June 8, 2026, April 20, 2026, and April 1, 2026, respectively. With an average price target of $9 between HC Wainwright & Co., Barclays, and BTIG, there's an implied 211.43% upside for Tvardi Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Barclays
BTIG
Piper Sandler
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for Tvardi Therapeutics
Loading calendar...
FAQ
What is the target price for Tvardi Therapeutics (TVRD) stock?
The latest price target for Tvardi Therapeutics (NASDAQ:TVRD) was reported by HC Wainwright & Co. on June 8, 2026. The analyst firm set a price target for $9.00 expecting TVRD to rise to within 12 months (a possible 183.02% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Tvardi Therapeutics (TVRD)?
The latest analyst rating for Tvardi Therapeutics (NASDAQ:TVRD) was provided by HC Wainwright & Co., and Tvardi Therapeutics initiated their buy rating.
When was the last upgrade for Tvardi Therapeutics (TVRD)?
There is no last upgrade for Tvardi Therapeutics
When was the last downgrade for Tvardi Therapeutics (TVRD)?
The last downgrade for Tvardi Therapeutics Inc happened on April 20, 2026 when Barclays changed their price target from $4 to $3 for Tvardi Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Tvardi Therapeutics (TVRD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tvardi Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tvardi Therapeutics was filed on June 8, 2026 so you should expect the next rating to be made available sometime around June 8, 2027.
Is the Analyst Rating Tvardi Therapeutics (TVRD) correct?
While ratings are subjective and will change, the latest Tvardi Therapeutics (TVRD) rating was a initiated with a price target of $0.00 to $9.00. The current price Tvardi Therapeutics (TVRD) is trading at is $3.18, which is within the analyst’s predicted range.
